Literature DB >> 32032511

Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.

Marie R Webster, Mitchell E Fane, Gretchen M Alicea, Subhasree Basu, Andrew V Kossenkov, Gloria E Marino, Stephen M Douglass, Amanpreet Kaur, Brett L Ecker, Keerthana Gnanapradeepan, Abibatou Ndoye, Curtis Kugel, Alexander Valiga, Jessica Palmer, Qin Liu, Xiaowei Xu, Jessicamarie Morris, Xiangfan Yin, Hong Wu, Wei Xu, Cathy Zheng, Giorgos C Karakousis, Ravi K Amaravadi, Tara C Mitchell, Filipe V Almeida, Min Xiao, Vito W Rebecca, Ying-Jie Wang, Lynn M Schuchter, Meenhard Herlyn, Maureen E Murphy, Ashani T Weeraratna.   

Abstract

Entities:  

Year:  2020        PMID: 32032511      PMCID: PMC7441646          DOI: 10.1016/j.molcel.2020.01.005

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


× No keyword cloud information.
  3 in total

Review 1.  New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.

Authors:  Mourad Zerfaoui; Titilope Modupe Dokunmu; Eman Ali Toraih; Bashir M Rezk; Zakaria Y Abd Elmageed; Emad Kandil
Journal:  Cells       Date:  2021-02-10       Impact factor: 6.600

2.  ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4.

Authors:  Jia Liu; Feng Cao; Xiaojie Li; Li Zhang; Zhengrong Liu; Xiaodong Li; Jingrong Lin; Chuanchun Han
Journal:  Cell Death Dis       Date:  2021-05-02       Impact factor: 8.469

3.  p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration.

Authors:  Pinakin Pandya; Lyubov Kublo; Jacob Stewart-Ornstein
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.